Recombinant Human coronavirus SARS spike glycoprotein (Tagged) is a SARS-CoV-2 Fragment protein, expressed in Escherichia coli, with >95% purity and suitable for ELISA, WB, SDS-PAGE.
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application ELISA | Reactivity Reacts | Dilution info - | Notes - |
Application WB | Reactivity Reacts | Dilution info - | Notes - |
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes May appear as multiple bands on SDS-PAGE (intact protein at 38 kDa, GST fusion protein at 26 kDa and the Nucleocapsid fragment at 12 kDa). |
Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:32155444, PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32075877, PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270). Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein
Recombinant Human coronavirus SARS spike glycoprotein (Tagged) is a SARS-CoV-2 Fragment protein, expressed in Escherichia coli, with >95% purity and suitable for ELISA, WB, SDS-PAGE.
Constituents: 50% Glycerol (glycerin, glycerine), 0.4% Tris HCl, 0.4% Sodium-N-Lauroylsarcosinate, 0.25% Triton X-100
GS-4B Sepharose-Affinity Purification.
Spike protein S1
Belongs to the betacoronaviruses spike protein family.
The cytoplasmic Cys-rich domain is palmitoylated. Palmitoylated spike proteins drive the formation of localized ordered cholesterol and sphingo-lipid-rich lipid nanodomains in the early Golgi, where viral budding occurs.
Contains GST fusion partner. Immunoreactive with SARS positive sera.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
The SARS spike glycoprotein also known as the S glycoprotein is a critical component of the SARS-CoV-2 virus. It weighs approximately 180 kDa and can be found on the surface of the viral envelope. The spike glycoprotein facilitates the entry of the virus into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. This protein is often targeted by monoclonal antibodies and vaccine strategies aimed at preventing infection. Researchers isolate antibodies that bind specifically to the spike contributing to the development of therapeutic agents like anti-spike monoclonal antibodies.
The spike glycoprotein serves a fundamental role in the viral life cycle by mediating fusion between the viral membrane and host cell membranes. Its function is divided into two subunits: S1 which is responsible for receptor binding and S2 which is important for membrane fusion. Upon receptor binding a conformational change in the glycoprotein occurs triggering fusion events critical for viral entry. This protein is not typically part of a larger complex but operates in tandem with viral envelope proteins to facilitate replication.
The spike glycoprotein's interaction with the host cell's ACE2 receptor places it within the renin-angiotensin-aldosterone system (RAAS) affecting several downstream signaling pathways. The binding initiates endocytosis of the virus into the host cell and impacts inflammation pathways and immune response mechanisms involving interleukin proteins. The spike protein shares functional relationships with other viral proteins such as nucleocapsid and membrane proteins contributing to the virion's structure and infection process.
The spike glycoprotein is closely associated with COVID-19 and the disease's ability to spread and mutate. It's a central focus in the development of potential treatments and vaccines given its role in viral entry. Some mutations in the spike protein can enhance transmissibility or resistance to neutralization influencing the course of infection. In seeking therapeutic interventions researchers focus on spike-related interactions with host proteins like ACE2 which are important in managing COVID-19 symptoms and complications.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Indirect ELISA showing primary antibody Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - Chicken IgY (Chimeric) ab323001 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera) ab272106) and Recombinant Human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - Chicken IgY (Chimeric) ab323001 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Chicken IgY H&L (HRP, Goat Anti-Chicken IgY H&L (HRP) ab6877) was used at 1:5000.
Indirect ELISA showing primary antibody Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [8B12-C2] - Chicken IgY (Chimeric) ab322999 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera) ab272106) and Recombinant Human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [8B12-C2] - Chicken IgY (Chimeric) ab322999 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Chicken IgY H&L (HRP, Goat Anti-Chicken IgY H&L (HRP) ab6877) was used at 1:5000.
Indirect ELISA showing primary antibody Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - Human IgG1 (Chimeric) ab323000 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera) ab272106) and Recombinant human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [EPR24852-116] - Human IgG1 (Chimeric) ab323000 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Human IgG Fc (HRP) preadsorbed (Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624) was used at 1:5000.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com